Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.
Pregnancy category AU: D
Routes of administration By mouth
Complement C5a receptor antagonist
The most common side effects include nausea, headache, decrease in white blood cell count, upper respiratory tract infection, diarrhea, vomiting, and nasopharyngitis.
It is the first orally-administered inhibitor of the complement C5a receptor approved by the US Food and Drug Administration.
The FDA considers it to be a first-in-class medication.
It is indicated as an adjunctive treatment of adults with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids.
Avacopan, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.